This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Diving into the EDIT-301 ASH Clinical Data Abstract and the approval of CASGEVY & Lyfgenia
Ticker(s): EDIT, BLUE, CRSP, VRTX, BBIOWho's the expert?
- stopped seeing patients in Feb 2022
- Remains active with 2 SCD grants submitting a manuscript to Haematologica
Interview GoalThis interview aims to explore the results and clinical insights garnered from the Phase I/II RUBY and EdiThal studies evaluating EDIT-301, a novel gene-edited autologous hematopoietic stem cell therapy, in patients with severe sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT). We will focus on understanding the safety, efficacy, and implications of this innovative approach for managing these hereditary blood disorders. We will also discuss the recent approvals from Bluebird Bio and Crispr Therapeutics.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
